|
시장보고서
상품코드
2016456
전신홍반루푸스 치료제 시장 : 약물 종류별, 투여 경로별, 지역별(2026-2034년)Systemic Lupus Erythematosus Drugs Market by Drug Class (Antimalarials Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic and Immunosuppressive Drugs, Biologics, and Others), Mode of Delivery, and Region 2026-2034 |
||||||
세계의 전신홍반루푸스(SLE) 치료제 시장 규모는 2025년에 30억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 48억 달러에 달하고, 2026년부터 2034년까지 CAGR 5.32%로 성장할 것으로 예측했습니다. SLE 환자 수 증가, 인식 개선 캠페인의 활성화, 제네릭 의약품의 접근성 등이 시장을 견인하는 주요 요인으로 작용하고 있습니다.
전신홍반루푸스(SLE)는 다양한 임상 증상, 다기관 염증(MIS), 재발-완화형(RRMS)을 특징으로 하는 자가면역질환입니다. 피부, 관절, 신장, 뇌 등 신체의 많은 부위에 영향을 미칩니다. 일반적으로 다양한 유전적, 환경적, 호르몬적 요인에 의해 발생합니다. 그 증상으로는 피로, 관절통과 부종, 두통, 발진, 탈모, 빈혈, 혈액 응고 이상, 발열 등이 있습니다. SLE는 의료진의 증상 평가, 신체 검사, 흉부 X선 검사, 소변 검사, 혈액 검사를 통해 진단합니다. 관절의 통증과 뻣뻣함에 대한 항염증제, 발진에 대한 스테로이드 크림, 면역반응을 억제하는 코르티코스테로이드, 피부 트러블에 대한 항말라리아제 등을 사용하여 증상을 완화할 수 있습니다. 또한, 더 심한 경우에는 질병 변형 약물이나 면역 체계를 표적으로 하는 약물을 사용하기도 합니다. 이 외에도 면역계의 활동을 억제하는 다양한 면역억제제를 사용하여 치료합니다.
전신홍반루푸스(SLE) 치료제 시장 동향:
개인의 자가면역질환 유병률 증가와 SLE 환자 수 증가는 전 세계적으로 SLE 치료제 수요를 이끄는 주요 요인 중 하나입니다. 또한, SLE와 그 치료법에 대한 일반인들의 인식을 개선하기 위해 많은 연구기관과 진단기관에서 대책을 마련하고, 인식개선 캠페인을 전개하고 있습니다. 또한, 많은 국가의 정부 및 비정부기구(NGO)는 SLE 치료를 위한 새로운 치료법 개발 및 관련 약물 표적 발굴을 위한 다양한 프로그램에 투자하고 있습니다. 이와 더불어, 세계 헬스케어 인프라 및 진단 기술 향상을 위한 자금 지원 증가가 시장 성장을 견인하고 있습니다. 이와는 별도로 SLE의 통증, 염증, 경직 완화를 위한 다양한 제네릭 의약품이 오프라인 및 온라인 소매 채널을 통해 쉽게 구할 수 있다는 점도 시장 성장을 촉진하고 있습니다. 일반적으로 아스피린, 이부프로펜(모트린), 나프록센, 셀레콕시브(셀레브렉스), 디클로페낙(볼타렌), 디플루니살(드로비드), 피록시캄(펠덴)과 같은 일반의약품(OTC) 및 처방전이 필요한 비스테로이드성 항염증제(NSAIDs)가 포함됩니다. NSAIDs)가 포함됩니다. 또한, 하이드록시클로로퀸 제제의 사용 증가도 시장 성장에 기여하고 있습니다. 이와 더불어 SLE의 조기 진단과 치료의 이점에 대한 일반인과 의료진의 인식이 높아지면서 SLE 치료제의 전체 매출에도 영향을 미치고 있습니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 전신홍반루푸스 치료제 시장
제6장 시장 내역 : 약물 종류별
제7장 시장 내역 : 투여 경로별
제8장 시장 내역 : 지역별
제9장 촉진·억제·기회
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
제12장 가격 분석
제13장 경쟁 구도
KSM 26.05.06The global systemic lupus erythematosus (SLE) drugs market size reached USD 3.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 4.8 Billion by 2034, exhibiting a growth rate (CAGR) of 5.32% during 2026-2034. The increasing number of patients suffering from SLE, rising public awareness campaigns, and the easy availability of generic drugs represent some of the key factors driving the market.
Systemic lupus erythematosus (SLE) is an autoimmune medical condition characterized by protean clinical manifestations, multisystem inflammation (MIS), and a relapsing and remitting course (RRMS). It affects numerous parts of the body, including the skin, joints, kidneys, and brain. It is generally caused due to various genetic, environmental, and hormonal factors. Its symptoms include fatigue, joint pain and swelling, headache, rashes, hair loss, anemia, blood clotting, and fever. SLE is diagnosed by a healthcare provider using symptom assessments, physical examinations, chest X-rays, urinalysis, and blood tests. Its symptoms can be eased using anti-inflammatory drugs for joint pain and stiffness, steroid creams for rashes, corticosteroids to minimize the immune response, and antimalarial drugs for skin problems. It also uses disease-modifying drugs and targeted immune system agents for more severe cases. Besides this, it is treated using various immunosuppressive drugs that inhibit the activity of the immune system.
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET TRENDS:
The increasing prevalence of autoimmune diseases among individuals and the rising number of patients suffering from SLE represents one of the major factors driving the demand for SLE drugs around the world. Moreover, the rising number of research and diagnostics institutes are undertaking measures and introducing public awareness campaigns to educate individuals about SLE and its possible treatments. In addition, governments and non-governmental organizations (NGOs) of numerous countries are investing in various programs to develop novel therapeutics and identify relevant drug targets for the treatment of SLE. This, coupled with the increasing financing to improve healthcare infrastructure and diagnostic technologies worldwide, is impelling the market growth. Apart from this, the easy availability of various generic drugs for relieving pain, inflammation, and stiffness associated with SLE through offline and online retail channels is favoring the market growth. They generally involve over the counter (OTC) and prescription-based nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen (Motrin), naproxen, celecoxib (Celebrex), diclofenac (Voltaren), diflunisal (Dolobid), and piroxicam (Feldene). Furthermore, the increasing use of Hydroxychloroquine drugs is contributing to the market growth. Besides this, the growing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of SLE is influencing the overall sales of SLE drugs.
KEY MARKET SEGMENTATION:
Drug Class Insights:
- Antimalarials Drugs
- Chloroquine
- Hydroxychloroquine
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Cytotoxic and Immunosuppressive Drugs
- Cyclophosphamide
- Methotrexate
- Mycophenolate Mofetil
- Tacrolimus
- Cyclosporine
- Biologics
- Others
The report has also provided a detailed breakup and analysis of the systemic lupus erythematosus (SLE) drugs market based on the drug class. This includes antimalarials drugs (chloroquine and hydroxycholroquine), non-steroidal anti-inflammatory drugs (NSAIDS), cytotoxic and immunosuppressive drugs (cyclophophamide, methotrexate, mycophenolate mofetil, tacrolimus, and cyclosporine), biologics, and others. According to the report, cytotoxic and immunosuppressive drugs represented the largest segment.
Mode of Delivery Insights:
- Intravenous
- Subcutaneous
- Oral
Regional Insights:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for systemic lupus erythematosus (SLE) drugs. Some of the factors driving the North America systemic lupus erythematosus (SLE) drugs market included easy access to healthcare, the rising awareness about the benefits of early diagnosis and treatment of SLE, and the easy availability of various generic drugs.
COMPETITIVE LANDSCAPE:
The report has also provided a comprehensive analysis of the competitive landscape in the global systemic lupus erythematosus (SLE) drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AstraZeneca Plc, Aurinia Pharmaceuticals Inc., GSK plc, and ImmuPharma Plc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
KEY QUESTIONS ANSWERED IN THIS REPORT
1. How big is the global Systemic Lupus Erythematosus (SLE) drugs market?
2. What is the expected growth rate of the global Systemic Lupus Erythematosus (SLE) drugs market during 2026-2034?
3. What are the key factors driving the global Systemic Lupus Erythematosus (SLE) drugs market?
4. What has been the impact of COVID-19 on the global Systemic Lupus Erythematosus (SLE) drugs market?
5. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the drug class?
6. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the mode of delivery?
7. What are the key regions in the global Systemic Lupus Erythematosus (SLE) drugs market?
8. Who are the key players/companies in the global Systemic Lupus Erythematosus (SLE) drugs market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Systemic Lupus Erythematosus (SLE) Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Drug Class
- 6.1 Antimalarials Drugs
- 6.1.1 Market Trends
- 6.1.2 Key Segments
- 6.1.2.1 Chloroquine
- 6.1.2.2 Hydroxychloroquine
- 6.1.3 Market Forecast
- 6.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Cytotoxic and Immunosuppressive Drugs
- 6.3.1 Market Trends
- 6.3.2 Key Segments
- 6.3.2.1 Cyclophosphamide
- 6.3.2.2 Methotrexate
- 6.3.2.3 Mycophenolate Mofetil
- 6.3.2.4 Tacrolimus
- 6.3.2.5 Cyclosporine
- 6.3.3 Market Forecast
- 6.4 Biologics
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Mode of Delivery
- 7.1 Intravenous
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Subcutaneous
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Oral
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 Drivers, Restraints, and Opportunities
- 9.1 Overview
- 9.2 Drivers
- 9.3 Restraints
- 9.4 Opportunities
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 AstraZeneca Plc
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Aurinia Pharmaceuticals Inc.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.3 GSK plc
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 ImmuPharma Plc
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.1 AstraZeneca Plc
